STAAR Surgical Announces Stockholder Meeting Results on Merger

STAAR Surgical Company, a leader in the development of phakic intraocular lenses (IOLs), announced on January 6, 2026, that it did not secure sufficient support from stockholders to approve its merger agreement with Alcon. This outcome was revealed during a Special Meeting of Stockholders held in Lake Forest, California.

According to preliminary estimates from STAAR’s proxy solicitor, the company was unable to gather the necessary votes from its investors to move forward with the merger. The proposed agreement aimed to enhance STAAR’s position in the vision correction market, particularly with its EVO family of Implantable Collamer® Lenses, commonly referred to as EVO ICLs.

The merger, which was anticipated to create significant synergies between STAAR and Alcon, will not proceed as planned, given the lack of stockholder backing. This decision underscores the complexities involved in corporate mergers, especially in the medical technology sector, where stakeholder sentiment plays a crucial role.

STAAR had expressed optimism about the merger prior to the meeting, highlighting potential benefits for both companies in terms of innovation and market expansion. However, the current outcome suggests that investor confidence may need to be reassessed.

The company’s shares are traded on the NASDAQ under the ticker symbol STAA, and they will likely experience fluctuations in response to this announcement. Market analysts will be closely watching how STAAR navigates the aftermath of this decision and what strategies it will employ moving forward.

The implications of this failed merger could reverberate through the organization, affecting its operational plans and future growth initiatives. Stakeholders will likely seek clarity from STAAR’s management in the coming days regarding the next steps for the company and its vision for the future of its product offerings.

As the situation develops, both STAAR and Alcon will need to engage with their respective investor bases and communicate effectively to maintain confidence in their strategic directions. This event serves as a reminder of the challenges companies face in achieving alignment with their shareholders, particularly when significant corporate changes are on the table.